30
APR
2018

NW Bio Announces Additional Funding

Posted By :
Comments : Off
 CEO Increases Year to Date Funding to $5.4 Million   BETHESDA, Md., April 30, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, increased her funding to the Company by $1 million, reaching a total of $5.4 million this year to date. On April 26, 2018, the Company and Ms. Powers entered into a...
Read More
19
DEC
2017

NW Bio Announces Regulation D Offering for Accredited Investors

Posted By :
Comments : Off
Financing Responds to Shareholder Requests Following Recent Series A Preferred Stock Financing BETHESDA, Md., December 19, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) — (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is commencing a general solicitation Regulation D offering  to accredited investors.  The Offering will remain open for execution...
Read More
04
DEC
2017

NW Bio Announces Completion of $12 Million Financing

Posted By :
Comments : Off
 Majority of Financing from New Investors BETHESDA, Md., December 4, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NWBio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has completed a $12 million financing to fund operations.  The majority of the financing is being provided by new investors. The financing is in the form of Series A Convertible Preferred Stock and...
Read More
20
NOV
2017

NW Bio Issues Notice Of Proposed Agreement To Settle Shareholder Derivative Lawsuit

Posted By :
Comments : Off
Notice Being Issued to Fulfill Settlement Agreement Condition    BETHESDA, Md., November 20, 2017 ­– Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to have reached an agreement to settle the derivative lawsuit captioned Wells v. Powers, et al., which was filed on November 28, 2016 in the Circuit...
Read More
25
OCT
2017

NW Bio Reports Favorable Results and Progress In Resolving Lawsuits

Posted By :
Comments : Off
3 Cases Substantially Completed, 4th Case Pending Completion,  No Monetary Damages Contemplated   Bethesda, MD, October 24, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company’s...
Read More